Search | IOVS | ARVO Journals

View

Showing 1 – 15 of 15

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

A topical VEGF inhibitor optimized for ocular indications

Stephen H Poor; Christopher Adams; Chad E Bigelow; Debby Long; Penny Yao; Elizabeth Fassbender; Siyuan Shen; Jim Chastain; Yubin Qiu; Bruce D Jaffee

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1975. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

Systemic VEGF Inhibition does not modulate ocular inflammatory cell infiltrate in the murine laser-induced choroidal neovascularization (CNV) Model

Adrian Will-Orrego; Sha-Mei Liao; Yubin Qiu; Elizabeth Fassbender; Siyuan Shen; Namrata Kotagiri; Bruce D Jaffee; Stephen H Poor

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3323. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

Ocular inflammatory cell infiltrates and angiogenesis are augmented by administration of the toll-like receptor-2 (TLR-2) ligand in a mouse model of choroidal neovascularization (CNV)

Stephen H Poor; Yubin Qiu; Adrian Will-Orrego; Elizabeth Fassbender; Siyuan Shen; Maura Crowley; Sha-Mei Liao; Bruce D Jaffee

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):484. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2015

A vascular endothelial growth factor receptor inhibitor (VEGFRi) achieves topical efficacy in rat and monkey models of choroidal neovascularization (CNV)

Stephen H Poor; Yubin Qiu; Amber Woolfenden; Debby Long; Christopher M Adams; Jason Elliott; Vinayak Hosagrahara; Jeremy M Sivak; Bruce D Jaffee

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3380. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2015

Weekly oral delivery of a vascular endothelial growth factor receptor (VEGFR) inhibitor compound optimized for ocular exposure improves safety and maintains efficacy compared to daily dosing

Yubin Qiu; Siyuan Shen; Elizabeth S Fassbender; Amber Woolfenden; Debby Long; Ron Newton; Erik Meredith; Bruce D Jaffee; Stephen H Poor; Ophthalmology, Novartis Institutes for BioMedical Research, Inc.

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):151. doi: https://doi.org/

Retina October 2014

Reliability of the Mouse Model of Choroidal Neovascularization Induced by Laser Photocoagulation

PDF

Stephen H. Poor; Yubin Qiu; Elizabeth S. Fassbender; Siyuan Shen; Amber Woolfenden; Andrea Delpero; Yong Kim; Natasha Buchanan; Thomas C. Gebuhr; Shawn M. Hanks; Erik L. Meredith; Bruce D. Jaffee; Thaddeus P. Dryja
TAGS: choroidal neovascularization, lasers, light coagulation, mice, reliability
Invest. Ophthalmol. Vis. Sci.. 2014; 55(10):6525-6534. doi: https://doi.org/10.1167/iovs.14-15067

Includes: Supplemental Content

ARVO Annual Meeting Abstract April 2014

Recombinant human vascular endothelial growth factor165(VEGF) derived from different expression systems does not affect in vitro, but does impact in vivo activity profiles

Yubin Qiu; Chad E Bigelow; Luciana Ferrara; Siyuan Shen; Michael P Maker; Elizabeth Fassbender; Yong Kim; Andrea DeErkenez; Barrett Leehy; Stephen H Poor

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):600. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2014

Intravitreal (IVT) injection exacerbates murine choroidal neovascularization (CNV) area by a MYD88 dependent mechanism

Elizabeth Fassbender; Yubin Qiu; Siyuan Shen; Amber Woolfenden; Andrea Delpero; Yong Kim; Bruce D Jaffee; Stephen H Poor

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1194. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2013

EphA2 Stimulation of Angiogenesis is Dependent on VEGFR2

Luciana Ferrara; Andrea De Erkenez; Elizabeth Fassbender; Siyuan Shen; Amber Woolfenden; Yubin Qiu; Stephen Poor; Karen Anderson; Bruce Jaffee

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5613. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2013

Validation and Characterization of Murine Oxygen-induced Retinopathy of Prematurity Model

Yubin Qiu; Amber Woolfenden; Wei Zheng; Karen Anderson; Melinda Hubbard; John Demirs; Joseph Loureiro; Joy Ghosh; Stephen Poor; Bruce Jaffee

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):617. doi: https://doi.org/

ARVO Annual Meeting Abstract March 2012

In Vitro And In Vivo Response Of VEGFR-2 To VEGF165 With/Without Ranibizumab

Amber Woolfenden; Elizabeth Fassbender; Siyuan Shen; Kathyrn McAllister; Lisa Baker; Bruce D. Jaffee; Stephen H. Poor; Yubin Qiu

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2962. doi: https://doi.org/

ARVO Annual Meeting Abstract March 2012

Complement Play A Minor Role In Mouse Laser-induced Choroidal Neovascularization

Stephen H. Poor; Elizabeth Fassbender; Siyuan Shen; Yubin Qiu; Amber Woolfenden; John Demirs; Karen Anderson; Bruce D. Jaffee

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1642. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2011

Analysis of Laser-induced Choroidal Neovascularization (CNV) Area from 143 Control Cohorts

Siyuan Shen; Yubin Qiu; Elizabeth Fassbender; Amber Woolfenden; Bruce D. Jaffee; Stephen H. Poor

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3974. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2011

Intravitreal Ranibizumab Inhibits Injected VEGF-induced Pathology In Rabbits Up To 9 Weeks After A Single Injection

Stephen H. Poor; Chad E. Bigelow; Yubin Qiu; Shawn M. Hanks; Elizabeth Fassbender; Siyuan Shen; Amber Woolfenden; Bruce D. Jaffee

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):972. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2011

Development of a Rabbit Model to Assess Anti-Angiogenic Therapies that Modulate Human VEGF-Mediated Retinal Vessel Pathology

Chad E. Bigelow; Stephen Poor; Yubin Qiu; Shawn M. Hanks; Michael Maker; Elizabeth Fassbender; Siyuan Shen; Amber Woolfenden; Bruce D. Jaffee

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1384. doi: https://doi.org/

Advertisement